DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Precose (Acarbose) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

PRECOSE SUMMARY

PRECOSE®
(acarbose tablets)

PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus.

PRECOSE®, as monotherapy, is indicated as an adjunct to diet to lower blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be managed on diet alone. PRECOSE® may also be used in combination with a sulfonylurea when diet plus either PRECOSE® or a sulfonylurea do not result in adequate glycemic control. Also, PRECOSE® may be used in combination with insulin or metformin. The effect of PRECOSE® to enhance glycemic control is additive to that of sulfonylureas, insulin, or metformin when used in combination, presumably because its mechanism of action is different.

In initiating treatment for type 2 diabetes mellitus, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling blood glucose and symptoms of hyperglycemia. The importance of regular physical activity when appropriate should also be stressed. If this treatment program fails to result in adequate glycemic control, the use of PRECOSE® should be considered. The use of PRECOSE® must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.


See all Precose indications & dosage >>

PRECOSE NEWS HIGHLIGHTS

Published Studies Related to Precose (Acarbose)

Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. [2008.06]

[A multicenter randomized controlled clinical trial on blood glucose lowering effects of domestic Acarbose (capsule) in type 2 diabetic patients] [2007.11]

Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. [2007.08]

Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. [2007.07]

Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. [2006.10]

more >>

Clinical Trials Related to Precose (Acarbose)

AI(I)DA Acarbose and the Subclinical Inflammation [Completed]

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients [Completed]

Efficacy and Safety of Repaglinide, GlurenormŽ and GlucobayŽ in Chineese Subjects With Type 2 Diabetes [Completed]

A Pilot Study of Acarbose as Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD) [Recruiting]

Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes [Recruiting]

more >>

Page last updated: 2008-08-11

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008